Living insulin implant developed to mimic pancreatic function

An international research team has developed a living implant designed to function like a miniature pancreas, potentially eliminating the need for daily insulin injections in patients with type 1 diabetes. The technology, presented in the journal Science Translational Medicine, uses live cells that act as both sensors and producers: they detect rising glucose levels and respond by releasing the necessary insulin.

A major hurdle in cellular therapy has been the body’s immune response, where macrophages and other immune cells attack the implant, causing inflammation and fibrous tissue buildup that blocks nutrient and insulin flow. To combat this, researchers introduced a “crystalline shield.” This innovation uses drug crystals that inhibit the CSF1R receptor, reducing the activity of monocytes and macrophages to protect the implant and ensure its survival within the organism. While the technology has shown promising results in animal testing, it is not yet available as a clinical treatment.